While we have seen a significant decline in opioid prescribing, new medications are diversifying the drivers of pharmacy costs in workers’ compensation. New trends are emerging from dermatologicals to anticonvulsants, specialty medications and emerging psychedelics. Of course, all bring unique challenges related to efficacy, safety, cost and potential for abuse – all which deepen the need for insurers to continually monitor closely moving forward.

Panelists:

Stanley Evans, Partner, Gerber Ciano Kelly Brady LLP                

Marty Rosemann, Head of Transaction and Legacy Management, Senior VP, Swiss Re

Anthony Sambucini, Chief Executive Officer, ANS Solutions 

Troy Smith, Assistant Vice President Claims, Arch

Kimberly Marsh, Vice President, National Accounts, ANS Solutions (Chair)